Swiss drugmaker Novartis has agreed to acquire Anthos Therapeutics, a Boston, US-based biopharmaceutical company with its lead compound abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
